North East and North Cumbria
ICS Formulary
ICS Formulary
4 Central nervous system
04-02-01 Antipsychotic Drugs
For more information on prescribing oral antipsychotics in primary care see:
NENC Oral Antipsychotics - Safe Prescribing Pathway
Links
MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs- MHRA Drug Safety Alert (Oct 2017): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
- MHRA Drug Safety Update (Aug 2020): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
- MHRA Drug Safety Update (December 2023): Aripiprazole (Abilify and generic brands): risk of pathological gambling
- MHRA Drug Safety Update (Nov 2013): Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery
- MHRA Drug Safety Update Dec 2021: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
NENC Palliative and End of Life Care Symptom Control Guidelines- NICE CG103: Delirium
- NICE CG178: Psychosis and schizophrenia in adults: prevention and management
- NICE NG10: Violence and aggression: short-term management in mental health, health and community settings
- NICE NG11: Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges
- NICE NG62: Cerebral palsy in under 25s: assessment and management
- NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
- NICE TA292: Bipolar disorder (children) - aripiprazole
- North East and North Cumbria ICB - Clozapine supporting guidance for primary care
- NTAG - Lurasidone Treatment Appraisal: Decision Summary
- TEWV - Medicines Optimisation – Interactive Guide
- TEWV Guidelines
- TEWV High Dose Antipsychotic Treatment (HDAT)
- TEWV Rapid Tranquilisation Policy
- TEWV Safe Transfer of Prescribing Guidance